Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04624425
Other study ID # REC/00710 Asma Baig
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 9, 2020
Est. completion date December 20, 2020

Study information

Verified date January 2021
Source Riphah International University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To determine the effects of segmental breathing exercise and buteyko breathing exercises on chest expansion in individuals with asthma. To determine the effects of segmental breathing exercise and buteyko breathing exercises on pulmonary function (FEV1, FVC, FEV1/FVC) in individuals with asthma. To determine the effects of segmental breathing exercise and buteyko breathing exercises on Asthma Control Questionnaire in individuals with asthma.


Description:

The National Heart and Lung Institute determines asthma as a common chronic airway disease distinguished by variable and reoccurring manifestations, bronchial hypersensitivity, reducing the flow of air in and out of the lungs and inflammatory reactions with in air passages in the lungs. Earlier in the first place asthma is also defined as existence of spontaneously reversible airway obstruction or with treatment and narrowing of airways also increased to different stimuli i.e. abrupt changes in weather, cold air, histamine, dust, pollen, feathers, exercise, viral upper respiratory infection, animal dander, cigarette smoke, fungal spores or respiratory allergens that increases bronchial hypersensitivity. segmental breathing technique is used for increasing the expansion of chest in individual's having empyema whose expansion has been decreased. Total 40 individuals with empyema were included in this study. Chest expansion at three levels have been checked i.e. at axilla level, at sternum level and at xiphoid level were examined before and after implementation of segmental exercise technique. Segmental breathing techniques play a major role in expansion of damaged lungs and as a consequence integral to rehabilitation of Respiratory disease. The effectiveness of segmental breathing technique and deep breathing exercise on expansion of chest and pulmonary function test. The physical therapy treatment comprises of dyspnea alleviating positions, simple breathing exercises, and exercises for thoracic expansion, inspiratory muscle training with incentive spirometers. Segmental breathing techniques are used to give support or enhance expansion of restricted lung in respiratory disorder. This technique is meant to have an effect on variation of mechanism, involving the stretch reflex process. Fast stretch on external intercostal muscles brings on assistance in contraction. Intercostal stretching with breathing control exercises might be more effective in enhancing lung parameters. This may also take part in ventilator capacity like tidal volume, saturation of oxygen and minute ventilation. Intercostal stretching might have stimulated the receptors of stretch mechanism in chest wall, hence distend the thoracic cavity which would have connected to medulla oblongata with nerve cell. The efficacy of buteyko method on control of asthma and quality of living in individuals with asthma. The buteyko breathing exercise is non-medical method that had shown to be better in reducing the frequency and seriousness of asthma. The interventional group manifested a considerable improvement in control of asthma score and quality of living score after four weeks. The other control group didn't manifest any improvement. This study suggested that buteyko breathing exercise may upgrade the physical, societal, spiritual and occupational effect on asthma and improved quality of living. The combined effect of buteyko breathing exercise and walking exercise on peak expiratory flow. The experimental group was specified for the combination of buteyko exercises and walking exercise for duration of eight weeks, three times per week and of 55 minutes of training session. The benefit of this technique is hold interval that can decrease overuse of carbon dioxide (CO2) that will control breath rate with the help of medulla oblongata in respiratory center, providing Nitric oxide (NO) which particular has bronchodilator effect. These both exercises minimise inflammatory reaction so that they decrease the sign and symptoms of asthma.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date December 20, 2020
Est. primary completion date December 20, 2020
Accepts healthy volunteers No
Gender All
Age group 20 Years to 45 Years
Eligibility Inclusion Criteria: - Individuals with clinical diagnosis of asthma. Exclusion Criteria: - Participants with unbearable chest pain, chylothorax, hemothorax, pneumothorax. - Participants with pleura disorder and chest trauma & rib fracture.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Segmental breathing exercises
Segmental breathing exercises along with the Conventional Treatment of buteyko breathing exercises for two weeks of duration. Segmental breathing exercises include 18-20 breaths in one session (6 breaths/min) with rest interval after every 6 breaths.
Buteyko breathing exercises
Buteyko exercises for two weeks of duration. Treatment session will be last for 10-15minutes.

Locations

Country Name City State
Pakistan Nusrat Abdul Rauf Centre for Enablement (NACE) Faisalabad Punjab

Sponsors (1)

Lead Sponsor Collaborator
Riphah International University

Country where clinical trial is conducted

Pakistan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Forced Expiratory Volume in 1 second (FEV1) Changes from the Baseline, the digital spirometer is used in clinical setting to analyze Forced Expiratory Volume in 1 second FEV1 in Liters 2 weeks
Primary Forced vital Capacity (FVC) Changes From the Baseline, the digital spirometer is used in clinical setting to analyze Forced vital Capacity in Liters. 2 weeks
Primary Modified Borg Scale of Perceived Exertion Changes from the Baseline, It is a subjective numeric scale ranging from 0 to 10, where 0 indicates "no dyspnea" and 10 indicates "unbearable dyspnea." A number is chosen by the patient in order to decide the best score that matches his level of dyspnea during physical activity. 2 weeks
Primary Chest Expansion measurement at Axillary level A measuring tape with centimeters scale will be used for measuring the expansion at Axillary level. Changes from the baseline will be measured. 2 weeks
Primary Chest Expansion measurement at Spinal cord T4 level A measuring tape with centimeters scale will be used for measuring the expansion at at Spinal cord T4 level. Changes from the baseline will be measured. 2 weeks
Primary Chest Expansion measurement at xiphoid process A measuring tape with centimeters scale will be used for measuring the expansion at xiphoid process level. Changes from the baseline will be measured. 2 weeks
Primary Asthma Control Questionnaire Measurement of the adequateness of asthma control and modifications in asthma control which may occurs immediately or as a consequence of treatment. It is a 7-point scale (0=no impairment, 6= maximum impairment for symptoms and rescue use; and 7 categories for FEV1%). Scores range between 0 (totally controlled) and 6 (severely uncontrolled) .The 7-items Asthma Control Questionnaire (ACQ) is valid to measure the goals of asthma management as defined by international guideline. Changes from the baseline will be measured. 2 weeks
See also
  Status Clinical Trial Phase
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
Completed NCT04102800 - Benralizumab Exacerbation Study Phase 4